Humane Genomics key facts
as of Oct 2026- Developer of a synthetic virology platform designed to engineer oncolytic viral therapies for cancer treatment.
- Humane Genomics is valued at approximately $17.0M as of Oct 2026 (last reported valuation).
- It has raised $8.1M; the latest was Seed Round ($8.0M) in Feb 2025.
- Notable investors include Y Combinator, Creative Destruction Lab, Mana Ventures, Gaingels, University of Toronto — 17 tracked in total.
- Status: Privately Held (backing).
Humane Genomics's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Humane Genomics: the Monday email on marks, rounds and moves
Humane Genomics funding rounds
No funding rounds for Humane Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Humane Genomics
17+Humane Genomics valuation
Humane Genomics's last reported valuation was $17 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Humane Genomics investors
17 investors are on record for Humane Genomics, including Y Combinator, Creative Destruction Lab, Mana Ventures and Gaingels. By type, the record holds 10 venture capital firms.
About Humane Genomics
Developer of a synthetic virology platform designed to engineer oncolytic viral therapies for cancer treatment. The company's platform offers RNA-based viral therapies with selective infection, high lytic activity, and systemic delivery, enabling cancer patients to receive targeted, safe, and effective treatment with extended therapeutic duration.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 6
- Website
- humanegenomics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.